Regulus Therapeutics Inc.
RGLS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $21 | $0 | $0 |
| Gross Profit | -$0 | -$21 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $35 | $21 | $18 | $18 |
| G&A Expenses | $15 | $10 | $10 | $10 |
| SG&A Expenses | $15 | $10 | $10 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$21 | $0 | -$0 |
| Operating Expenses | $50 | $10 | $28 | $27 |
| Operating Income | -$50 | -$31 | -$28 | -$28 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4 | $1 | -$0 | $0 |
| Pre-Tax Income | -$46 | -$30 | -$28 | -$28 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$46 | -$30 | -$28 | -$28 |
| % Margin | – | – | – | – |
| EPS | -0.82 | -1.58 | -1.86 | -3.24 |
| % Growth | 48.1% | 15.1% | 42.6% | – |
| EPS Diluted | -0.82 | -1.58 | -1.86 | -3.24 |
| Weighted Avg Shares Out | 56 | 19 | 15 | 9 |
| Weighted Avg Shares Out Dil | 56 | 19 | 15 | 9 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $2 | $1 | $1 |
| Interest Expense | $0 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$46 | -$31 | -$28 | -$27 |
| % Margin | – | – | – | – |